Ads
related to: boehringer ingelheim respiratory products
Search results
Results From The WOW.Com Content Network
(Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...
The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD), AstraZeneca said. Boehringer had also said it ...
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
Boehringer is a FDA-registered medical device company located in Phoenixville, PA founded by Jack Boehringer in 1972. The company initially released a line of anesthesia and respiratory care instruments, followed by suction regulators and autologous blood transfusion products.
3 Largest selling pharmaceutical products of 2015. 4 Best selling pharmaceuticals of 2013. ... Boehringer Ingelheim: Chronic obstructive pulmonary disease: Apr-2002: ...
Respimat, also known as Respimat Soft Mist Inhaler, is a drug delivery device used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its developer, Boehringer Ingelheim , is currently [ when? ] conducting approved in the U.S. with a variety of their products, such as tiotropium and ...